Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow Mounjaro and Wegovy differ, and why that rules out combining them
You've been reading about both pens. Here's what's actually happening in each.
Imagine you've spent a few evenings reading about weight-loss injections and noticed that Mounjaro (tirzepatide, made by Eli Lilly) and Wegovy (semaglutide, made by Novo Nordisk) both reduce appetite, both slow gastric emptying, and both produce meaningful weight loss in clinical trials. It's a reasonable leap to wonder whether using both medicines together might accelerate things further.
The reality is more nuanced. Mounjaro is a dual GIP and GLP-1 receptor agonist, the only licensed weight-loss medicine in the UK that activates both pathways. Wegovy acts on the GLP-1 receptor alone. Because Mounjaro already engages the GLP-1 receptor fully, adding Wegovy would not open a fresh mechanism; it would pile a second GLP-1 stimulus on top of one that's already running, with no licensed evidence that this improves outcomes and a clear reason to expect amplified nausea, vomiting and other gastrointestinal side effects. The NHS medicines page for tirzepatide and its counterpart for semaglutide each list the GI side-effect profile individually, combining the two would act on those risks simultaneously.
Neither medicine's licensed indication covers co-administration with the other. No published UK clinical guidance recommends it. In practice, the question isn't whether combining them is faster, it's which single medicine is the better clinical match for you.
What the trial evidence actually shows, separately
Looking at the two medicines head to head helps explain why the question of combining them comes up. In the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. SURMOUNT-1 (72 weeks, over 2,500 participants) recorded average body-weight reductions of around 20–21% at the 15mg tirzepatide dose. Separately, the STEP 1 trial for semaglutide 2.4mg found an average reduction of around 15% over 68 weeks.
The table below sets out the key factual differences between the two licensed UK options.
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide injection) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Licensed UK doses | 2.5, 5, 7.5, 10, 12.5, 15 mg weekly | 0.25 mg to 2.4 mg (or 7.2 mg) weekly |
| Average weight loss (trial) | ~20–21% at 15 mg (SURMOUNT-1, NEJM) | ~15% at 2.4 mg (STEP 1, NEJM) |
| Administration | Once-weekly subcutaneous injection, KwikPen | Once-weekly subcutaneous injection, pre-filled pen |
| Storage | Refrigerated 2–8°C (check SmPC for room-temp window) | Refrigerated 2–8°C (check SmPC for room-temp window) |
| Can be combined with the other? | No, not licensed, not clinically indicated | |
Both pens live in the fridge, which is why patients often describe the same routine: pen at the back of the top shelf, out on injection day, back in before the door swings shut. You only need space for one.
What about switching, rather than stacking?
The question our prescribers hear fairly often is a variation on this: someone on Wegovy who isn't seeing the results they hoped for asks whether adding Mounjaro, or switching to it, makes sense. Switching is a legitimate clinical conversation. Comparing Wegovy and Mounjaro on their own terms (mechanism, tolerability, your health history, your current dose, how long you've been on treatment) is exactly what a structured consultation is for.
Stacking is different. If you're curious whether taking Mounjaro and Wegovy together could offer any advantage, the short answer is that it would mean two medicines competing for overlapping receptors, with double the GI burden and no supporting evidence. For more on why semaglutide and tirzepatide together isn't a licensed or recommended approach, the underlying pharmacology is consistent with everything covered here.
The right question isn't "can I use both?", it's "which one gives me the best foundation?" That is a clinical decision, made with our prescribers, based on your BMI, health conditions, and how your body has responded to treatment so far. If you're weighing the two options, cost context for both medicines in the UK is also worth understanding before you decide.
Neither Ozempic nor Rybelsus is licensed for weight management in the UK, both are semaglutide, but licensed for type 2 diabetes only, and prescribing either for weight loss sits outside their UK authorisation.
If you'd like a prescriber to review which medicine is clinically appropriate for you, start your free consultation and a GPhC-registered Independent Prescriber will review your case the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.